Skip to main content

Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 253-261 out of 318 results.
NCT04266249

EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in Patients who Achieve a Pathologic Complete Response, Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to Optimize Therapy in HER2-positive Breast Cancer)

Icon for trial | EA1181 EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in Patients who Achieve a Pathologic Complete Response, Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to Optimize Therapy in HER2-pos

This study is being done to answer the following question. Can participants with HER2-positive breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after 12 weeks of chemotherapy ...

NCT06253130

EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors

Icon for trial | EIK1003-001 (IMP1734-101) EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tum

The study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in the future. The study treatm ...